Glyburide in Women With Mild Gestational Diabetes: A Randomized Controlled Trial

Brian M. Casey, MD, Elaine L. Duryea, MD, Mina Abbassi-Ghanavati, MD, Carmen M. Tudela, MD, Stephan A. Shivvers, MD, Donald D. McIntire, PhD, and Kenneth J. Leveno, MD

(Obstet Gynecol 2015;126:303–9)

1. What is the incidence of gestational diabetes in the population served by your center or clinic? Outline the current treatment protocol or practice at your center regarding the management of patients with gestational diabetes. Identify any similarities and differences between the American College of Obstetricians and Gynecologists’ Practice Bulletin (no. 137, Gestational Diabetes Mellitus, Obstet Gynecol 2013;122:406–16) and your institution’s protocol.

2. Identify the primary objective and hypothesis of this study. How do these compare with those of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network’s gestational diabetes study by Landon et al (see N Engl J Med 2009;361:1339–48)? Discuss the importance and relevance of the current study question to your patient population.

3. Briefly outline how the authors accomplished both concealment of allocation and blinding during the randomization of participants. Refer to the Consolidated Standards of Reporting Trials (CONSORT) Statement (see http://www.consort-statement.org/) and discuss any strengths and weaknesses of the randomization scheme and blinding.

4. Summarize the criteria used to determine the sample size for the study. Discuss whether or not you would use the same criteria if given the opportunity to design a study to address the same primary objective.

5. Review the eligibility (see Figure 1) and characteristics (see Table 2) of the study population. Discuss whether or not these data are applicable to the population at your center or practice.

6. What proportion of patients was lost to follow-up? Do you think the results would be different if delivery information was available on all patients? Why or why not?

7. The authors conclude, “Overall, the findings in this study suggest that the addition of glyburide to dietary treatment in women with mild gestational diabetes offers no additional benefit.” Discuss why you agree or disagree with this statement.